Genetic Variants Influencing Circulating Lipid Levels and Risk of Coronary Artery Disease

Grants

Funding Acknowledgements

This work was supported by the United Kingdom Medical Research Council, Wellcome Trust (WT), British Heart Foundation, European Commission, and GlaxoSmithKline. Specifically, we acknowledge use of genotype data from the 1958 British birth cohort DNA collection, funded by Medical Research Council Grant G0000934 and Wellcome Trust Grant 068545/Z/02. Dr Barroso and Dr Wheeler acknowledge support from European Union FP6 funding (contract no LSHM-CT-2003-503041). Dr Sandhu and Dr Ricketts are funded by the British Heart Foundation (PG/08/094) and Medical Research Council (G0801566). Dr Barroso (077016/Z/05/Z), Dr Peltonen, Dr Inouye, and Dr Deloukas are funded by the Wellcome Trust. Some computation was done on the Vital-IT system at the Swiss Institute of Bioinformatics. The Ottawa Heart Study is funded by HSFO NA6001 and CIHR. The GEMS study was sponsored in part by GlaxoSmithKline. The CoLaus study was supported by grants from GlaxoSmithKline, the Swiss National Science Foundation (Grant 33CSCO-122661) and the Faculty of Biology and Medicine of Lausanne. This research used resources provided by the Type 1 Diabetes Genetics Consortium (T1DGC), a collaborative clinical study sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Allergy and Infectious Diseases, National Human Genome Research Institute, National Institute of Child Health and Human Development, and Juvenile Diabetes Research Foundation International (JDRF) and was supported by U01 DK062418. The T1DGC GWAS project was funded by the National Institute of Diabetes and Digestive and Kidney Diseases and JDRF and was coordinated by the JDRF/WT Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research (Cambridge, United Kingdom), which is funded by the JDRF International, the Wellcome Trust, and the National Institute for Health Research Cambridge Biomedical Research Center. The Cambridge Institute for Medical Research is in receipt of a Wellcome Trust Strategic Award (079895). Recruitment of the PennCATH cohort was supported by the Cardiovascular Institute of the University of Pennsylvania. Genotyping for the PennCATH cohort was performed at the Center for Applied Genomics at the Children's Hospital of Philadelphia and supported by GlaxoSmithKline through an Alternate Drug Discovery Initiative research alliance award (to M.P.R. and D.J.R.) with the University of Pennsylvania School of Medicine. The Rotterdam Study was supported by the Netherlands Organisation for Scientific Research (NWO Groot, 175.010.2005.011, 911.03.012), the Research Institute for Diseases in the Elderly (RIDE2, 01493015), and the Netherlands Genomic Initiative (NGI/NWO) (050-060-810). NFBC 1966 received financial report from the Academy of Finland (project Grants 104781, 120315, 1114194, Center of Excellence in Complex Disease Genetics), University Hospital Oulu, Biocenter, University of Oulu, Oulu, Finland, National Heart, Lung, and Blood Institute Grant 5R01HL087679-02 through the STAMPEED program (1RL1MH083268-01), ENGAGE project and grant agreement HEALTH-F4-2007-201413, the Medical Research Council (G0500539, PrevMetSyn/Medical Research Council), and the Wellcome Trust (GR069224), United Kingdom. The DNA extractions, sample quality controls, biobank upkeep, and aliquotting were performed in the National Public Health Institute, Biomedicum, Helsinki, Finland, supported financially by the Academy of Finland and Biocentrum Helsinki.